Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Transcept Pharmaceuticals News: Roumell Asset Management’s Thoughts on Retrophin

Transcept Pharmaceuticals news: Transcept Pharmaceuticals Inc (NASDAQ:TSPT) is a small-cap stock that recently was cut slightly in the equity portfolio of Roumell Asset Management, a hedge fund managed by Jim Roumell. In a recent amendment to the 13D filing with the SEC, filed yesterday, Roumell expressed his position regarding Retrophin’s intention to acquire Transcept Pharmaceuticals, which states that the offering price of $4 per share offered by Retrophin is too small, and has no value in regard to Transcept’s first FDA-approved product, Intermezzo.

James Roumell

Earlier in September, Roumell Asset Management disclosed ownership of around 2.0 million shares of Transcept, the value of the position amounting to some $7.5 million. In comparison with the latest 13F filed by the hedge fund, Roumell dropped around 318,200 shares.

“Roumell Asset Management is Transcept’s largest shareholder.  In light of Retrophin, Inc.’s offer to purchase the company on September 18, 2013, it is incumbent upon the Board to hire an investment banker to solicit additional interest.  It is the fiduciary duty of this Board to begin this process immediately.  We believe the Retrophin offer of $4 per share is woefully inadequate, as it is basically a return of the company’s cash with little or no value ascribed to Intermezzo.  To be clear, we no longer, at current prices, believe the company should buy back stock, but rather begin a fair and open auction process for a sale of the entire company,” the hedge fund said in the filing.

“In our minds, if the company is able to get back the full rights of Intermezzo from Purdue Pharma, and thus roughly $18 million in revenue, there will be material interest in purchasing this revenue stream.  A company like Retrophin can very profitably add such a stream to its portfolio, while incurring minimal marketing costs.  Transcept’s bloated cost structure will make profitability extremely challenging, if not unlikely, as it currently exists.

“We believe there is a solid chance to reclaim Intermezzo from Purdue given that Purdue is no longer actively marketing the drug and the valid reputational concern that it not be viewed as just sitting on the drug without meeting its contractual obligations.  We believe Intermezzo’s current revenue is sticky and would be highly profitable for the right buyer.

“A price of $60 million for Intermezzo, which would result in roughly $7 per share for Transcept shareholders, would still leave a buyer with a likely free cash flow yield exceeding 20%.  This analysis is based on industry contacts who have informed us that a 90% gross margin would not be unrealistic for Intermezzo.  If Transcept is unable to repossess Intermezzo on its own, we believe there are companies willing to put their efforts toward that end and will pay for that optionality,” the filing added.

Aside from Roumell, Renaissance Technologies, managed by Jim Simons, Israel Englander’s Millennium Management, and D. E. Shaw’s D E Shaw & Co are long. Stay tuned for updates on any further Transcept Pharmaceuticals news from the hedge fund world.

Recommended Reading:

Why I’m Buying Markel

Smithfield Foods-Starboard Value Situation Takes a New Turn

Warren Buffett Portfolio: How He’s Playing The Small-Caps

Disclosure: none

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.